TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company’s Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation.
In June, Xagenic also announced it has acquired exclusive rights to a mutation detection technology with potential applications to liquid biopsy testing. The electrochemical clamp assay technology was developed by University of Toronto Professor and Xagenic Founder (now CTO) Dr. Shana Kelley. Genome Web covered the news in June and July 2015.
“This investment round is a testament to the faith our existing investors have in the power of the Xagenic X1™ platform and the promise of our enzyme-free approach to molecular diagnostics,” said Timothy I. Still, Xagenic’s CEO. “This funding will accelerate our development efforts in bringing our point-of-care diagnostic platform to market.”
Xagenic’s rapid, lab-free, molecular diagnostic system affords a large market opportunity created by a significant, unmet medical need for point-of-care diagnostic solutions. Because of its highly scalable, consumables-driven business model, Xagenic is well-positioned to capitalize on this opportunity with a differentiated product offering and unique menu strategy.